239 related articles for article (PubMed ID: 21875484)
21. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
22. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jung M; Kim SH; Hong S; Kang YA; Kim SK; Chang J; Rha SY; Kim JH; Kim DJ; Cho BC
Yonsei Med J; 2012 Sep; 53(5):931-9. PubMed ID: 22869475
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib in the treatment of advanced squamous cell NSCLC.
Fiala O; Pesek M; Finek J; Krejci J; Havel L; Hrnciarik M; Salajka F; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(6):676-82. PubMed ID: 23906302
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
26. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Nishio M; Yamanaka T; Matsumoto K; Kimura H; Sakai K; Sakai A; Sone T; Horiike A; Koizumi F; Kasahara K; Ohira T; Ikeda N; Saijo N; Arao T; Nishio K
J Thorac Oncol; 2011 Nov; 6(11):1889-94. PubMed ID: 21964526
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
[TBL] [Abstract][Full Text] [Related]
29. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
[TBL] [Abstract][Full Text] [Related]
30. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
[TBL] [Abstract][Full Text] [Related]
32. [Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy].
Zhang F; Xing LN
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):873-5. PubMed ID: 19173837
[TBL] [Abstract][Full Text] [Related]
33. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
34. Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Huang KT; Chen HC; Chang YC; Lin MC
Medicine (Baltimore); 2015 Dec; 94(50):e2239. PubMed ID: 26683939
[TBL] [Abstract][Full Text] [Related]
35. Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
Fiala O; Pesek M; Finek J; Krejci J; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(2):129-34. PubMed ID: 23259780
[TBL] [Abstract][Full Text] [Related]
36. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
Lin GN; Peng JW; Liu PP; Liu DY; Xiao JJ; Chen XQ
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e189-e194. PubMed ID: 25359280
[TBL] [Abstract][Full Text] [Related]
37. The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected].
Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
Anticancer Res; 2014 Sep; 34(9):5193-8. PubMed ID: 25202114
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
39. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
40. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]